ARG1 and myeloproliferative disorder: During the last decade cancer immune therapy based on targeting immunosuppressive mechanisms has shown great potential in treatment of solid tumors (3) and several of the key known immunosuppressive pathways such as programmed death ligand-1 (PD-L1) and arginase1 (ARG1) have also been identified in MPN (4–6).